Established and recent developments in the pharmacological management of urolithiasis: an overview of the current treatment armamentarium

References

• Knoll T. Epidemiology, pathogenesis and pathophysiology of urolithiasis. Eur Urol Suppl. 2010;9(12):802–806.
   Web of Science ®Google Scholar
• Brikowski TH, Lotan Y, Pearle MS. Climate-related increase in the prevalence of urolithiasis in the United States. Proc Natl Acad Sci U S A. 2008;105(28):9841–9846.
   PubMed Web of Science ®Google Scholar
• Chen Z, Prosperi M, Bird VY. Prevalence of kidney stones in the USA: the national health and nutrition evaluation survey. J Clin Urol. 2019;12(4):296–302.
   Web of Science ®Google Scholar
• Worcester EM, Coe FL. Nephrolithiasis. Prim Care. 2008;35(2):369–vii.
   PubMed Web of Science ®Google Scholar
• Borghi L, Meschi T, Amato F, et al. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: a 5 year randomized prospective study. J Urol. 1996;155(3):839–843.
   PubMed Web of Science ®Google Scholar
• Ljunghall S, Danielson BG. A prospective study of renal stone recurrence. B J Urol. 1984;56:122–124.
   PubMedGoogle Scholar
• Lotan Y, Cadeddu JA, Roerhborn CG, et al. Cost-effectiveness of medical management strategies for nephrolithiasis. J Urol. 2004;172(6 Pt 1):2275–2281.
   PubMed Web of Science ®Google Scholar
• Park S, Pearle MS. Urolithiasis: update on metabolic evaluation of stone formers. ScientificWorldJournal. 2005;5:902–914.
   PubMedGoogle Scholar
• Tiselius HG, Daudon M, Thomas K, et al. Metabolic work-up of patients with urolithiasis: indications and diagnostic algorithm. Eur Urol Focus. 2017;3(1):62–71.
   PubMedGoogle Scholar
• Fink HA, Akorno R, Garimella PS, et al. Diet, fluid, or supplements for secondary prevention of nephrolithiasis: a systematic review and meta-analysis of randomized trials. Eur Urol. 2009 Jul;56(1):72–80.
   PubMed Web of Science ®Google Scholar
• Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med. 2002;346(2):77–84.
   PubMed Web of Science ®Google Scholar
• Escribano J, Balaguer A, Roqué I Figuls M, et al. Dietary interventions for preventing complications in idiopathic hypercalciuria. Cochrane Database Syst Rev. 2014 Feb 11;(2):CD006022.
   PubMed Web of Science ®Google Scholar
• Trinchieri A. Diet and renal stone formation. Minerva Med. 2013;104(1):41–54.
   PubMed Web of Science ®Google Scholar
• Coll DM, Varanelli MJ, Smith RC. Relationship of spontaneous passage of ureteral calculi to stone size and location as revealed by unenhanced helical CT. AJR Am J Roentgenol. 2002;178(1):101–103.
   PubMed Web of Science ®Google Scholar
• Miller OF, Kane CJ. Time to stone passage for observed ureteral calculi: a guide for patient education. J Urol. 1999;162(3Pt 1):688–90. discussion 690–1.
   PubMedGoogle Scholar
• Campschroer T, Zhu Y, Duijvesz D, et al. Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev. 2014 Apr 2;(4):CD008509.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Hergan LA, Sakamoto K, et al. Efficacy of alpha-blockers for the treatment of ureteral stones. J Urol. 2007;177(3):983–7; discussion 987.
   PubMed Web of Science ®Google Scholar
• Yilmaz E, Batislam E, Basar MM, et al. The comparison and efficacy of 3 different alpha1-adrenergic blockers for distal ureteral stones. J Urol. 2005;173(6):2010–2012.
   PubMed Web of Science ®Google Scholar
• Sun X, He L, Ge W, et al. Efficacy of selective alpha1D-blocker naftopidil as medical expulsive therapy for distal ureteral stones. J Urol. 2009;181(4):1716–1720.
   PubMed Web of Science ®Google Scholar
• Liu XJ, Wen JG, Wan YD, et al. Role of silodosin as medical expulsive therapy in ureteral calculi: a meta-analysis of randomized controlled trials. Urolithiasis. 2018;46(2):211–218.
   PubMed Web of Science ®Google Scholar
• Hollingsworth JM, Rogers MA, Kaufman SR, et al. Medical therapy to facilitate urinary stone passage: a meta-analysis. Lancet. 2006;30;368(9542):1171–1179.
   Web of Science ®Google Scholar
• Seitz C, Liatsikos E, Porpiglia F, et al. Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol. 2009;56(3):455–471.
   PubMed Web of Science ®Google Scholar
• Cao D, Yang L, Liu L, et al. A comparison of nifedipine and tamsulosin as medical expulsive therapy for the management of lower ureteral stones without ESWL. Sci Rep. 2014;4:5254.
   PubMed Web of Science ®Google Scholar
• Porpiglia F, Vaccino D, Billia M, et al. Corticosteroids and tamsulosin in the medical expulsive therapy for symptomatic distal ureter stones: single drug or association? Eur Urol. 2006;50(2):339–344.
   PubMed Web of Science ®Google Scholar
• Saita A, Bonaccorsi A, Marchese F, et al. Our experience with nifedipine and prednisolone as expulsive therapy for ureteral stones. Urol Int. 2004;72(Suppl 1):43–45.
   PubMedGoogle Scholar
• Gratzke C, Uckert S, Reich O, et al. PDE5 inhibitors. A new option in the treatment of ureteral colic? Urologe A. 2007;46(9):1219–1223.
   PubMedGoogle Scholar
• Kumar S, Jayant K, Agrawal S, et al. Comparative efficacy of tamsulosin versus tamsulosin with tadalafil in combination with prednisolone for the medical expulsive therapy of lower ureteric stones: a randomized trial. Korean J Urol. 2014;55(3):196–200.
   PubMedGoogle Scholar
• Bai Y, Yang Y, Wang X, et al. Tadalafil facilitates the distal ureteral stone expulsion: a meta-analysis. J Endourol. 2017;31(6):557–563.
   PubMed Web of Science ®Google Scholar
• Türk C, Skolarikos A, Neisius A, et al. Guidelines on urolithiasis. Eur Assoc Urol. 2019. available from: http://uroweb.org/guideline/urolithiasis/.
   PubMedGoogle Scholar
• Assimos D, Krambeck A, Miller NL, et al. surgical management of stones: American urological association/endourological society guideline, PART II. J Urol. 2016 Oct;196(4):1161–1169.
   PubMedGoogle Scholar
• Fedrigon DC, Jain R, Sivalingam S. Current use of medical expulsive therapy among endourologists. Can Urol Assoc J. 2018;12(9):E384–E390.
   Web of Science ®Google Scholar
• Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002;31(4):927–949.
   PubMed Web of Science ®Google Scholar
• Chaudhary A, Singla SK, Tandon C. In vitro evaluation of terminalia arjuna on calcium phosphate and calcium oxalate crystallization. Indian J Pharm Sci. 2010;72(3):340–345.
   PubMed Web of Science ®Google Scholar
• Penniston KL, Nakada SY. Updates in the metabolic management of calcium stones. Curr Urol Rep. 2018;19(6):41.
   PubMed Web of Science ®Google Scholar
• Craven BL, Passman C, Assimos DG. Hypercalcemic states associated with nephrolithiasis. Rev Urol. 2008;10(3):218–226.
   PubMedGoogle Scholar
• Worcester EM, Coe FL. New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol. 2008;28(2):120–132.
   PubMed Web of Science ®Google Scholar
• Brocks P, Dahl C, Wolf H, et al. Do thiazides prevent recurrent idiopathic renal calcium stones? Lancet. 1981;2(8238):124–125.
   PubMed Web of Science ®Google Scholar
• Scholz D, Schwille PO, Sigel A. Double-blind study with thiazides in recurrent calcium lithiasis. J Urol. 1982;128(5):903–907.
   PubMed Web of Science ®Google Scholar
• Robertson WG, Peacock M, Selby PL, et al. A multicentre trial to evaluate three treatments for recurrent idiopathic calcium stone disease—a preliminary report. Urol Res. 1985;12:48.
   Google Scholar
• Mortensen JT, Schultz A, Ostergaard AH. Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones. Int Urol Nephrol. 1986;18(3):265–269.
   PubMedGoogle Scholar
• Ettinger B, Citron JT, Livermore B, et al. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol. 1988;139(4):679–684.
   PubMed Web of Science ®Google Scholar
• Ohkawa M, Tokunaga S, Nakashima T, et al. Thiazide treatment for calcium urolithiasis in patients with idiopathic hypercalciuria. Br J Urol. 1992;69(6):571–576.
   PubMedGoogle Scholar
• Borghi L, Meschi T, Guerra A, et al. Randomized prospective study of a nonthiazide diuretic, indapamide, in preventing calcium stone recurrences. J Cardiovasc Pharmacol. 1993;22(suppl 6):S78–S86.
   PubMed Web of Science ®Google Scholar
• Wilson DR, Strauss AL, Manuel MA. Comparison of medical treatment for the prevention of recurrent calcium nephrolithiasis. Urol Res. 1984;12:39–40.
   Google Scholar
• Fernández-Rodríguez A, Arrabal-Martín M, García-Ruiz MJ, et al. The role of thiazides in the prophylaxis of recurrent calcium lithiasis. Actas Urol Esp. 2006;30(3):305–309.
   PubMedGoogle Scholar
• Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis. Acta Med Scand. 1984;215(4):383–389.
   PubMed Web of Science ®Google Scholar
• Ahlstrand C, Sandvall K, Tiselius HG. Prophylactic treatment of calcium stone formers with hydrochlorothiazide and magnesium. Edsbruk, Sweden: Akademitryck; 1996.
   Google Scholar
• Vigen R, Weideman RA, Reilly RF. Thiazides diuretics in the treatment of nephrolithiasis: are we using them in an evidence-based fashion? Int Urol Nephrol. 2011;43(3):813–819.
   PubMed Web of Science ®Google Scholar
• Alexander RT, McArthur E, Jandoc R, et al. Thiazide diuretic dose and risk of kidney stones in older adults: a retrospective cohort study. Can J Kidney Health Dis. 2018;5:2054358118787480.
   Google Scholar
• Martins MC, Meyers AM, Whalley NA, et al. Indapamide (Natrilix): the agent of choice in the treatment of recurrent renal calculi associated with idiopathic hypercalciuria. Br J Urol. 1996;78(2):176–180.
   PubMedGoogle Scholar
• Ceylan K, Topal C, Erkoc R, et al. Effect of indapamide on urinary calcium excretion in patients with and without urinary stone disease. Ann Pharmacother. 2005;39(6):1034–1038. Epub 2005 Apr 19.
   PubMed Web of Science ®Google Scholar
• Bergsland KJ, Worcester EM, Coe FL. Role of proximal tubule in the hypocalciuric response to thiazide of patients with idiopathic hypercalciuria. Am J Physiol Renal Physiol. 2013;305(4):F592–F599.
   PubMed Web of Science ®Google Scholar
• Dhayat NA, Faller N, Bonny O, et al. Efficacy of standard and low dose hydrochlorothiazide in the recurrence prevention of calcium nephrolithiasis (NOSTONE trial): protocol for a randomized double-blind placebo-controlled trial. BMC Nephrol. 2018;19(1):349.
   PubMedGoogle Scholar
• Sica DA. Diuretic-related side effects: development and treatment. J Clin Hypertens (Greenwich). 2004;6(9):532–540.
   PubMedGoogle Scholar
• Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis risk in communities study. N Engl J Med. 2000;342(13):905–912.
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Blaufox MD, Oberman A, et al. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med. 1991;114(8):613–620.
   PubMed Web of Science ®Google Scholar
• Chang SW, Fine R, Siegel D, et al. The impact of diuretic therapy on reported sexual function. Arch Intern Med. 1991;151(12):2402–2408.
   PubMedGoogle Scholar
• Diffey BL, Langtry J. Phototoxic potential of thiazide diuretics in normal subjects. Arch Dermatol. 1989;125(10):1355–1358.
   PubMedGoogle Scholar
• Huen SC, Goldfarb DS. Adverse metabolic side effects of thiazides: implications for patients with calcium nephrolithiasis. J Urol. 2007;177(4):1238–1243.
   PubMed Web of Science ®Google Scholar
• Mandel EI, Taylor EN, Curhan GC. Dietary and lifestyle factors and medical conditions associated with urinary citrate excretion. Clin J Am Soc Nephrol. 2013;8(6):901–908.
   PubMed Web of Science ®Google Scholar
• Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol. 2009 Summer;11(3):134–144.
   PubMedGoogle Scholar
• Chow K, Dixon J, Gilpin S, et al. Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones. Kidney Int. 2004;65(5):1724–1730.
   PubMed Web of Science ®Google Scholar
• Pak CY, Poindexter JR, Adams-Huet B, et al. Predictive value of kidney stone composition in the detection of metabolic abnormalities. Am J Med. 2003;115:26–32.
   PubMed Web of Science ®Google Scholar
• Caudarella R, Vescini F. Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment. Arch Ital Urol Androl. 2009;81(3):182–187.
   PubMedGoogle Scholar
• Sheng X, Jung T, Wesson JA, et al. Adhesion at calcium oxalate crystal surfaces and the effect of urinary constituents. Proc Natl Acad Sci U S A. 2005;102(2):267–272.
   PubMed Web of Science ®Google Scholar
• Simpson DP. Citrate excretion: a window on renal metabolism. Am J Physiol. 1983;244(3):F223–F234.
   PubMedGoogle Scholar
• Phillips R, Hanchanale VS, Myatt A, et al. Citrate salts for preventing and treating calcium containing kidney stones in adults. Cochrane Database Syst Rev. 2015 Oct 6;(10):CD010057.
   PubMed Web of Science ®Google Scholar
• Barcelo P, Wuhl O, Servitge E, et al. Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol. 1993;150(6):1761–1764.
   PubMed Web of Science ®Google Scholar
• Hofbauer J, Höbarth K, Szabo N, et al. Alkali citrate prophylaxis in idiopathic recurrent calcium oxalate urolithiasis–a prospective randomized study. Br J Urol. 1994;73(4):362–365.
   PubMedGoogle Scholar
• Ettinger B, Pak CY, Citron JT, et al. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997;158(6):2069–2073.
   PubMedGoogle Scholar
• Cicerello E, Merlo F, Gambaro G, et al. Effect of alkaline citrate therapy on clearance of residual renal stone fragments after extracorporeal shock wave lithotripsy in sterile calcium and infection nephrolithiasis patients. J Urol. 1994;151(1):5–9.
   PubMed Web of Science ®Google Scholar
• Jiménez Verdejo A, Arrabal Martín M, Miján Ortiz JL, et al. Effect of potassium citrate in the prophylaxis of urinary lithiasis. Arch Esp Urol. 2001;54(9):1036–1046.
   PubMedGoogle Scholar
• Soygur T, Akbay A, Kupeli S. Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial. J Endourol. 2002;16(3):149–152.
   PubMed Web of Science ®Google Scholar
• Lojanapiwat B, Tanthanuch M, Pripathanont C, et al. Alkaline citrate reduces stone recurrence and regrowth after shockwave lithotripsy and percutaneous nephrolithotomy. Int Braz J Urol. 2011;37(5):611–616.
   PubMed Web of Science ®Google Scholar
• Carvalho M, Erbano BO, Kuwaki EY, et al. Effect of potassium citrate supplement on stone recurrence before or after lithotripsy: systematic review and meta-analysis. Urolithiasis. 2017;45(5):449–455.
   PubMed Web of Science ®Google Scholar
• Mattle D, Hess B. Preventive treatment of nephrolithiasis with alkali citrate-a critical review. Urol Res. 2005;33(2):73–79.
   PubMedGoogle Scholar
• Parks JH, Worcester EM, Coe FL, et al. Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. Kidney Int. 2004;66(2):777–785.
   PubMed Web of Science ®Google Scholar
• Mandel N, Mandel I, Fryjoff K, et al. Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J Urol. 2003;169(6):2026–2029.
   PubMed Web of Science ®Google Scholar
• Rimer JD, Sakhaee K, Maalouf NM. Citrate therapy for calcium phosphate stones. Curr Opin Nephrol Hypertens. 2019;28(2):130–139.
   PubMed Web of Science ®Google Scholar
• Preminger GM, Sakhaee K, Pak CY. Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. J Urol. 1988;139(2):240–242.
   PubMed Web of Science ®Google Scholar
• Fegan J, Khan R, Poindexter J, et al. Gastrointestinal citrate absorption in nephrolithiasis. J Urol. 1992;147(5):1212–1214.
   PubMed Web of Science ®Google Scholar
• Shenoy C. Hypocitraturia despite potassium citrate tablet supplementation. MedGenMed. 2006;8(3):8.
   PubMedGoogle Scholar
• Kang DE, Sur RL, Haleblian GE, et al. Long-term lemonade based dietary manipulation in patients with hypocitraturic nephrolithiasis. J Urol. 2007;177(4):1358–62; discussion 1362; quiz 1591.
   PubMed Web of Science ®Google Scholar
• Penniston KL, Steele TH, Nakada SY. Lemonade therapy increases urinary citrate and urine volumes in patients with recurrent calcium oxalate stone formation. Urology. 2007;70(5):856–860. Epub 2007 Oct 24
   PubMed Web of Science ®Google Scholar
• Nicar MJ, Peterson R, Pak CY. Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol. 1984;131(3):430–433.
   PubMed Web of Science ®Google Scholar
• Odvina CV, Preminger GM, Lindberg JS, et al. Long-term combined treatment with thiazide and potassium citrate in nephrolithiasis does not lead to hypokalemia or hypochloremic metabolic alkalosis. Kidney Int. 2003;63(1):240–247.
   PubMed Web of Science ®Google Scholar
• Asplin JR. Hyperoxaluric calcium nephrolithiasis. Endocrinol Metab Clin North Am. 2002;31(4):927–949.
   PubMed Web of Science ®Google Scholar
• Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75(12):1264–1271.
   PubMed Web of Science ®Google Scholar
• Cramer SD, Ferree PM, Lin K, et al. The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum Mol Genet. 1999;8(11):2063–2069.
   PubMed Web of Science ®Google Scholar
• Belostotsky R, Seboun E, Idelson GH, et al. Mutations in DHDPSL are responsible for primary hyperoxaluria type III. Am J Hum Genet. 2010;10;87(3):392–399.
   PubMed Web of Science ®Google Scholar
• Karaolanis G, Lionaki S, Moris D, et al. Secondary hyperoxaluria: a risk factor for kidney stone formation and renal failure in native kidneys and renal grafts. Transplant Rev (Orlando). 2014;28(4):182–187.
   PubMedGoogle Scholar
• Bhasin B, Ürekli HM, Atta MG. Primary and secondary hyperoxaluria: understanding the enigma. World J Nephrol. 2015;4(2):235–244.
   PubMedGoogle Scholar
• Cochat P, Hulton SA, Acquaviva C, et al. Primary hyperoxaluria type 1: indications for screening and guidance for diagnosis and treatment. Nephrol Dial Transplant. 2012;27:1729–1736.
   PubMed Web of Science ®Google Scholar
• Sikora P, von Unruh GE, Beck B, et al. Oxalate absorption in children with idiopathic calcium oxalate urolithiasis or primary hyperoxaluria. Kidney Int. 2008;73(10):1181–1186.
   PubMed Web of Science ®Google Scholar
• Hoppe B, Niaudet P, Salomon R, et al. A randomised phase I/II trial to evaluate the efficacy and safety of orally administered oxalobacter formigenes to treat primary hyperoxaluria. Pediatr Nephrol. 2017;32(5):781–790.
   PubMed Web of Science ®Google Scholar
• Cochat P, Liutkus A, Fargue S, et al. Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol. 2006;21(8):1075–1081. Epub 2006 Jun 30.
   PubMed Web of Science ®Google Scholar
• Pang R, Linnes MP, O’Connor HM, et al. Controlled metabolic diet reduces calcium oxalate supersaturation but not oxalate excretion after bariatric surgery. Urology. 2012;80(2):250–254.
   PubMed Web of Science ®Google Scholar
• Nordenvall B, Backman L, Larsson L, et al. Effects of calcium, aluminium, magnesium and cholestyramine on hyperoxaluria in patients with jejunoileal bypass. Acta Chir Scand. 1983;149(1):93–98.
   PubMedGoogle Scholar
• Lonsdale K. Epitaxy as a growth factor in urinary calculi and gallstones. Nature. 1968;217(5123):56–58.
   PubMed Web of Science ®Google Scholar
• Grover PK, Marshall VR, Ryall RL. Dissolved urate salts out calcium oxalate in undiluted human urine in vitro: implications for calcium oxalate stone genesis. Chem Biol. 2003;10(3):271–278.
   PubMedGoogle Scholar
• Ettinger B, Tang A, Citron JT, et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med. 1986;315(22):1386–1389.
   PubMed Web of Science ®Google Scholar
• Goldfarb DS, MacDonald PA, Gunawardhana L, et al. Randomized controlled trial of febuxostat versus allopurinol or placebo in individuals with higher urinary uric acid excretion and calcium stones. Clin J Am Soc Nephrol. 2013;8(11):1960–1967.
   PubMed Web of Science ®Google Scholar
• Arowojolu O, Goldfarb DS. Treatment of calcium nephrolithiasis in the patient with hyperuricosuria. J Nephrol. 2014;27(6):601–605.
   PubMed Web of Science ®Google Scholar
• Dawson CH, Tomson CR. Kidney stone disease: pathophysiology, investigation and medical treatment. Clin Med (Lond). 2012;12(5):467–471.
   PubMed Web of Science ®Google Scholar
• Buckalew VM Jr. Nephrolithiasis in renal tubular acidosis. J Urol. 1989;141(3 Pt 2):731–737.
   PubMed Web of Science ®Google Scholar
• Goldfarb DS. A woman with recurrent calcium phosphate kidney stones. Clin J Am Soc Nephrol. 2012;7(7):1172–1178.
   PubMed Web of Science ®Google Scholar
• Krieger NS, Asplin JR, Frick KK, et al. Effect of potassium citrate on calcium phosphate stones in a model of hypercalciuria. J Am Soc Nephrol. 2015;26(12):3001–3008.
   PubMed Web of Science ®Google Scholar
• Sakhaee K. Epidemiology and clinical pathophysiology of uric acid kidney stones. J Nephrol. 2014;27(3):241–245.
   PubMed Web of Science ®Google Scholar
• Ngo TC, Assimos DG. Uric acid nephrolithiasis: recent progress and future directions. Rev Urol. 2007 Winter;9(1):17–27.
   PubMedGoogle Scholar
• Pak CY, Sakhaee K, Peterson RD, et al. Biochemical profile of idiopathic uric acid nephrolithiasis. Kidney Int. 2001;60(2):757–761.
   PubMed Web of Science ®Google Scholar
• Shekarriz B, Stoller ML. Uric acid nephrolithiasis: current concepts and controversies. J Urol. 2002;168(4 Pt 1):1307–1314.
   PubMed Web of Science ®Google Scholar
• Cicerello E, Merlo F, Maccatrozzo L. Urinary alkalization for the treatment of uric acid nephrolithiasis. Arch Ital Urol Androl. 2010;82(3):145–148.
   PubMedGoogle Scholar
• Abou-Elela A. Epidemiology, pathophysiology, and management of uric acid urolithiasis: a narrative review. J Adv Res. 2017;8(5):513–527.
   PubMed Web of Science ®Google Scholar
• Sterrett SP, Penniston KL, Wolf JS Jr, et al. Acetazolamide is an effective adjunct for urinary alkalization in patients with uric acid and cystine stone formation recalcitrant to potassium citrate. Urology. 2008;72(2):278–281.
   PubMed Web of Science ®Google Scholar
• Wiederkehr MR, Moe OW. Uric acid nephrolithiasis: a systemic metabolic disorder. Clin Rev Bone Miner Metab. 2011;9(3–4):207–217.
   PubMedGoogle Scholar
• Mattoo A, Goldfarb DS. Cystinuria. Semin Nephrol. 2008;28(2):181–191.
   PubMed Web of Science ®Google Scholar
• Andreassen KH, Pedersen KV, Osther SS, et al. How should patients with cystine stone disease be evaluated and treated in the twenty-first century? Urolithiasis. 2016;44(1):65–76.
   PubMed Web of Science ®Google Scholar
• Ng CS, Streem SB. Contemporary management of cystinuria. J Endourol. 1999;13(9):647–651.
   PubMed Web of Science ®Google Scholar
• Joly D, Rieu P, Méjean A, et al. Treatment of cystinuria. Pediatr Nephrol. 1999;13(9):945–950.
   PubMed Web of Science ®Google Scholar
• Fjellstedt E, Denneberg T, Jeppsson JO, et al. A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria. Urol Res. 2001;29(5):295–302.
   PubMedGoogle Scholar
• Pak CY, Fuller C, Sakhaee K, et al. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol. 1986;136(5):1003–1008.
   PubMed Web of Science ®Google Scholar
• Thiola [package insert on the internet] mission pharmacal company. San Antonio, TX; 2018 [cited 2018 Jul 1]. Available from: http://www.retrophin.com/pdf/Thiola%20PI.pdf
   Google Scholar
• Sloand JA, Izzo JL Jr. Captopril reduces urinary cystine excretion in cystinuria. Arch Intern Med. 1987;147(8):1409–1412.
   PubMed Web of Science ®Google Scholar
• Cohen TD, Streem SB, Hall P. Clinical effect of captopril on the formation and growth of cystine calculi. J Urol. 1995;154(1):164–166.
   PubMed Web of Science ®Google Scholar
• Hu L, Yang Y, Aloysius H, et al. l-cystine diamides as l-cystine crystallization inhibitors for cystinuria. J Med Chem. 2016;59(15):7293–7298.
   PubMed Web of Science ®Google Scholar
• Lee MH, Sahota A, Ward MD, et al. Cystine growth inhibition through molecular mimicry: a new paradigm for the prevention of crystal diseases. Curr Rheumatol Rep. 2015;17(5):33.
   PubMed Web of Science ®Google Scholar
• Wilmer MJ, Willems PH, Verkaart S, et al. Cystine dimethylester model of cystinosis: still reliable? Pediatr Res. 2007;62(2):151–155.
   PubMed Web of Science ®Google Scholar
• Zee T, Bose N, Zee J, et al. α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria. Nat Med. 2017;23(3):288–290.
   PubMed Web of Science ®Google Scholar
• de Boer H, Roelofsen A, Janssens PM. Antidiuretic hormone antagonist to reduce cystine stone formation. Ann Intern Med. 2012;157(6):459–460.
   PubMed Web of Science ®Google Scholar
• Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;20;367(25):2407–2418.
   Web of Science ®Google Scholar
• Bichler KH, Eipper E, Naber K, et al. Urinary infection stones. Int J Antimicrob Agents. 2002;19(6):488–498.
   PubMed Web of Science ®Google Scholar
• Flannigan R, Choy WH, Chew B, et al. Renal struvite stones–pathogenesis, microbiology, and management strategies. Nat Rev Urol. 2014;11(6):333–341.
   PubMed Web of Science ®Google Scholar
• Jarrar K, Boedeker RH, Weidner W. Struvite stones: long term follow up under metaphylaxis. Ann Urol (Paris). 1996;30(3):112–117.
   PubMedGoogle Scholar
• Medical management of kidney stones. American Urological Association. 2014 Mar. [cited 2019 Nov 2]. Available from: https://www.auanet.org/guidelines/kidney-stones-medical-mangement-guideline.
   Google Scholar
• Griffith DP, Gleeson MJ, Lee H, et al. Randomized, double-blind trial of lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi. Eur Urol. 1991;20(3):243–247.
   PubMed Web of Science ®Google Scholar
• Williams JJ, Rodman JS, Peterson CM. A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis. N Engl J Med. 1984;311(12):760–764.
   PubMed Web of Science ®Google Scholar
• Griffith DP, Khonsari F, Skurnick JH, et al. A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients. J Urol. 1988;140(2):318–324.
   PubMed Web of Science ®Google Scholar
• Trinchieri A. Urinary calculi and infection. Urologia. 2014;81(2):93–98.
   PubMedGoogle Scholar